Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6195MR)

This product GTTS-WQ6195MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6195MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3728MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ7227MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ8965MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ13492MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ4692MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ9381MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ7804MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ15570MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW